Published in Vaccine Weekly, December 22nd, 2004
"This milestone marks a major turning point for our product commercialization plan," said William J. Gastle, President and CEO. "Initial manufacturing runs have been completed successfully and we hope to finish the next phase at an early date," he continued.
The market potential for urokinase is believed to be significant based on market analysis and discussions with physicians. "Hospitals need better access to affordable...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly